Updated: Oct 19
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
This case follows Mr. Tarek Nasser (alias), a 60-year-old patient from Egypt who arrived in China critically ill with large B-cell lymphoma and recovered enough within two months to walk out of the hospital on his own, following dual-target CAR-T cell therapy. Dual-target CAR-T addresses a known limitation of standard CD19-only CAR-T therapy: because DLBCL is highly heterogeneous, tumor cells can lose or downregulate a single targeted antigen and escape treatment.
For international patients with large B-cell lymphoma — including those who may be at risk of antigen escape or have already progressed after single-target CAR-T — ChinaCureLink can help evaluate access to this more advanced approach.
Key Takeaways |
|
Patient Background
Mr. Nasser arrived in China in critical condition. He was unable to sit up on his own, had a large abdominal mass, persistent diarrhea, and significant swelling throughout his body. Given the severity of his condition, the hospital's international department arranged an ambulance and staff to meet him and his family on arrival and transport him directly for evaluation.
The Care Team and Approach
Director Xu Wei (pseudonym) and the treating team from a JCI-accredited hematology hospital in China conducted a rapid, comprehensive evaluation and developed a personalized, precision treatment plan: local radiotherapy combined with dual-target CAR-T cell therapy targeting both CD19 and CD22.
Dual-target CAR-T therapy was designed specifically to address a known limitation of single-target CD19 CAR-T: because DLBCL is highly heterogeneous, tumor cells can lose or downregulate the CD19 antigen and escape treatment, allowing the disease to relapse. By targeting CD19 and CD22 simultaneously, this approach reduces the risk of that antigen escape, which has been associated with improved remission rates and a lower risk of drug resistance in patients with relapsed or refractory DLBCL.
As treatment progressed, Mr. Nasser gradually regained his physical strength. His tumor and abdominal mass shrank significantly, his diarrhea resolved, and the swelling subsided, with his overall condition improving substantially.
Treatment Timeline/ Process
Before Treatment
Diagnosed with large B-cell lymphoma; condition deteriorated to critical, with an inability to sit up independently, a large abdominal mass, persistent diarrhea, and significant swelling
At the Hospital
Met by ambulance and international department staff on arrival and transported directly for evaluation
Underwent a rapid, comprehensive assessment; began a personalized plan combining local radiotherapy and CD19/CD22 dual-target CAR-T cell therapy
Gradually regained strength as the tumor and abdominal mass shrank, diarrhea resolved, and swelling subsided
Day 28: PET/CT evaluation showed significant improvement in his condition
Two months: Physical condition returned to good health; discharged from the hospital, walking out on his own
Outcome
By day 28, PET/CT imaging confirmed a significant improvement in Mr. Nasser's condition. Within two months of starting treatment, he had gone from being unable to sit up on his own to walking out of the ward independently, and was discharged in good overall health. He and his family were moved enough by the experience to write a thank-you letter to the treating physicians, nursing team, and international department.
How ChinaCureLink Can Help International Patients to Access This Treatment
Patients with large B-cell lymphoma — particularly those at risk of relapse after single-target CAR-T therapy due to antigen loss — may benefit from a dual-target approach like the one Mr. Nasser received. ChinaCureLink helps international patients get a specialized case review and connects them with hospitals in China experienced in advanced CAR-T protocols, coordinating urgent logistics, medical record translation, and every step of care from first inquiry through treatment and follow-up — including arrival support for patients who are critically ill.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
What is dual-target CD19/CD22 CAR-T therapy, and how is it different from standard CAR-T?
Standard CAR-T therapy typically targets a single antigen, usually CD19. Dual-target CAR-T targets both CD19 and CD22 simultaneously, reducing the risk that tumor cells escape treatment by losing or downregulating one antigen, which can improve remission rates in heterogeneous cancers like DLBCL.
How can international patients access dual-target CAR-T therapy for large B-cell lymphoma in China?
Access typically begins with a case review, where medical records and diagnostic imaging are submitted for evaluation. ChinaCureLink coordinates this process, including urgent arrival logistics for critically ill patients, and helps match patients with hospitals experienced in advanced CAR-T protocols.
What does the treatment and recovery timeline look like for CAR-T therapy?
Timelines vary by case, but this patient showed significant improvement on imaging within 28 days and was well enough to be discharged within two months. Recovery depends on disease severity, treatment response, and individual health factors.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
